Marksans Pharma Ltd (MARKSANS)
₹246.30
Mkt cap
₹12,496 Cr
P/E ratio
29.90
P/B
3.69
Div yield
0.29%
ROE
15.20%
ROCE
18.80%
EPS (TTM)
₹8.24
Book value
₹67
52W range
157–277
Sector
Healthcare
Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products [1]
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−11.18% from high₹246
₹157+56.99% from low₹277
Current
₹246.30
Prev close
₹246.95
Day
−0.26%
Price performance
1D
−0.26%
1W
−7.74%
1M
−3.82%
3M
+29.49%
6M
+45.34%
1Y
−4.87%
YTD
+35.19%
Financials
FRevenue, profit & margin
P/E ratio
29.9×
MARKSANS is 14% below the sector median of 34.9×
MARKSANS29.9×
Sector median34.9×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 486 | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 | 720 | 754 | 856 | |
| Expenses | 376 | 398 | 417 | 453 | 450 | 462 | 495 | 543 | 582 | 520 | 576 | 594 | 661 | |
| Operating Profit | 110 | 102 | 114 | 133 | 110 | 128 | 147 | 139 | 127 | 100 | 144 | 161 | 195 | |
| OPM % | 23% | 20% | 21% | 23% | 20% | 22% | 23% | 20% | 18% | 16% | 20% | 21% | 23% | |
| Other Income | 11 | 10 | 19 | 5 | 17 | 15 | -0 | 28 | 15 | 6 | 22 | 20 | 35 | |
| Interest | 2 | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 | 6 | 6 | 6 | |
| Depreciation | 14 | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 | 27 | 24 | 24 | |
| Profit before tax | 104 | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 | 133 | 151 | 200 | |
| Tax % | 21% | 27% | 26% | 26% | 23% | 26% | 22% | 27% | 22% | 24% | 26% | 25% | 25% | |
| Net Profit | 83 | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 | 99 | 114 | 149 | |
| EPS in Rs | 1.81 | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 | 2.17 | 2.50 | 3.27 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
CLast 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
Sas of Mar 202643.87%Promoter
Promoters43.87%
FIIs16.76%8.63
DIIs6.57%0.66
Public32.78%9.30
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,951.50 | 37.73 | 4,68,821 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,273.00 | 73.61 | 1,93,075 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.96% |
| Torrent Pharma. | ₹5,017.80 | 77.52 | 1,69,902 | 0.76% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,438.00 | 30.52 | 1,16,168 | 0.90% | 543 | −54.61% | 6,541 | −2.80% | 15.49% |
| Zydus Lifesci. | ₹1,156.90 | 21.27 | 1,15,401 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,493.00 | 20.05 | 1,13,988 | 0.72% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,543.10 | 52.29 | 1,05,054 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.50% |
| Marksans Pharma | ₹275.75 | 29.90 | 12,496 | 0.29% | 149 | +63.59% | 856 | +20.84% | 18.84% |
| Median: 156 Co. | ₹434.68 | 34.87 | 2,006 | 0.08% | 12 | +22.43% | 177 | +16.46% | 15.19% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bseFinancial Year 2012bse
Concall transcripts55
TranscriptJun 2026PPTJun 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024TranscriptAug 2024PPTAug 2024RECAug 2024TranscriptJun 2024
Credit ratings6
Announcements5
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 10 Jul - Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release 8 Jul - Marksans Pharma to acquire 100% of ABCnow GmbH for €892,384 by 31 July 2026.Announcement under Regulation 30 (LODR)-Date of payment of Dividend 3 Jul - 34th AGM on 27 August 2026; record date 20 August; final dividend ₹0.90 per share.Announcement under Regulation 30 (LODR)-Dividend Updates 3 Jul - 34th AGM on 27 August 2026; record date 20 August 2026 for ₹0.90 final dividend.The Annual General Meeting Of The Marksans Pharma Limited Is Scheduled To Be Held On 27 August 2026. 3 Jul - 34th AGM on 27 August 2026; record date 20 August 2026 for ₹0.90 final dividend.